Glaucoma Treatment Market Report (2023 to 2031) – Alcon, Merck & Co., Inc., Novartis AG, Pfizer Inc., and AbbVie Inc.

Newark, New Castle, USA, June 13, 2023 (GLOBE NEWSWIRE) — The market analysis of the global glaucoma treatment market was conducted by Growth Plus Reports in 2022 and is valued at US$ 5.89 billion. The market is expected to hit a revenue CAGR of 3.4% to reach US$ 7.96 billion by 2031.

Analysis of the global market for glaucoma treatment indicates that the revenue share is likely to increase significantly. If left untreated, glaucoma affects the visual nerve and can result in permanent blindness. Reducing intraocular pressure, a substantial risk factor for glaucoma is the primary goal of treatment.

Key Takeaways: 

• The rising geriatric population is the main cause driving the global market revenue share.
• prescription drugs and surgical procedures are driving the market demand.
• The demand for novel and cutting-edge treatment alternatives is increasing the market revenue growth rapidly.

Request a Free Sample PDF: https://www.growthplusreports.com/inquiry/request-sample/glaucoma-treatment-market/8926

                                         Glaucoma Treatment Market Scope

Recent Development in the Glaucoma Treatment Market: 

• In August 2022, to expand its line of ophthalmic medications, Alcon purchased Aerie Pharmaceuticals, Inc. Through the deal, Alcon gained access to a pipeline of many clinical and preclinical ophthalmic pharmaceutical product candidates, as well as the commercial glaucoma treatments Rocklatan and Rhopressa, as well as AR-15512, a Phase 3 product candidate for dry eye illness.

Competitive Landscape

A list of the companies operating in the global market for glaucoma treatment includes: 

• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• Akorn Incorporated
• AbbVie Inc.

Market Drivers and Restraints: 

The global glaucoma treatment market revenue is driven by the rising prevalence of glaucoma, the growing geriatric population, rising research and development in drug discovery, and the installation of top-notch technologies in the healthcare sector. Furthermore, the increase in the surgical procedure for glaucoma treatment and favorable reimbursement policies also contribute to the market revenue growth. 

However, due to the expensive aspect of treatment and restricted patient access to care, the glaucoma treatment market revenue growth is expected to be restrained. 

Market Segmentation: 

• Based on indication, the global glaucoma treatment market is segmented into open-angle glaucoma, closed-angle glaucoma, secondary glaucoma, congenital glaucoma, and others. 
• Based on drug class, the global glaucoma treatment market is segmented into prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors, and others. 
• Based on the distribution channel, the global glaucoma treatment market is segmented into hospital, retail, and online pharmacies. 

Request for Customization – https://www.growthplusreports.com/inquiry/customization/glaucoma-treatment-market/8926

Segmentation By Drug Class

Based on the drug class, the prostaglandin analogs segment dominates the global glaucoma treatment market with the largest revenue share. They have revolutionized glaucoma therapy and are widely regarded as the first-line treatment for many patients, which accounts for their significant revenue share. Additionally, these medications lower intraocular pressure and work in the early and late stages of the illness, contributing to a large share of revenue. 

Regional Growth Dynamics

Based on the region, North America, with the largest revenue share, dominates the global glaucoma treatment market. The high prevalence of glaucoma in North America, as well as the area’s well-developed healthcare infrastructure, which includes state-of-the-art diagnostic tools and treatment facilities, are credited with this significant revenue share. In addition, the area gains from a flourishing research and development sector, where several academic institutions and pharmaceutical companies conduct glaucoma therapy trials.

Report Coverage 

Growth Plus Reports carried out extensive market research on the glaucoma treatment market globally. We examined the fundamental market characteristics, significant investment opportunities, regional growth patterns, ten-year revenue estimates, competing market players, and mergers and acquisitions.

Table of Content

1. INTRODUCTION
   1. Market Ecosystem
   2. Timeline Under Consideration
      1. Historical Years – 2021
      2. Base Year – 2022
      3. Forecast Years – 2023 to 2031
   3. Currency Used in the Report
2. RESEARCH METHODOLOGY 
   1. Research Approach
   2. Data Collection Methodology
   3. Data Sources
      1. Secondary Sources 
      2. Primary Sources 
   4. Market Estimation Approach
      1. Bottom Up
      2. Top Down 
   5. Market Forecasting Model
   6. Limitations and Assumptions
3. PREMIUM INSIGHTS
   1. Current Market Trends (COVID-19 Perspective)
   2. Key Players & Competitive Positioning (2022) 
   3. Regulatory Landscape
   4. Reimbursement Scenario 
4. MARKET DYNAMICS
   1. Drivers
   2. Restraints/Challenges
   3. Opportunities
5. GLOBAL GLAUCOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY INDICATION
   1. Open Angle Glaucoma
   2. Closed Angle Glaucoma
   3. Secondary Glaucoma
   4. Congenital Glaucoma
   5. Others
6. GLOBAL GLAUCOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY DRUG CLASS
   1. Prostaglandin Analogs
   2. Beta Blockers
   3. Alpha Agonist
   4. Carbonic Anhydrase Inhibitors
   5. Others
7. GLOBAL GLAUCOMA TREATMENT MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies  

GLAUCOMA TREATMENT MARKET TOC

Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8926

VALUE PROPOSITIONS RELATED TO THE REPORT:

• Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
• Comprehensive quantitative and qualitative insights at segment and sub-segment level
• Covid 19 impact trends and perspective
• Granular insights at global/regional/country level
• Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
• Blanket coverage on competitive landscape
• Winning imperatives
• Exhaustive coverage on ‘Strategic Developments’ registered by leading players of the market.

CUSTOMIZATION OPTIONS:

• Distributor Landscape Assessment
• Pricing Intelligence
• Customer Base Assessment
• Investment & Initiatives Analysis
• ‘Business Profile’ of Key Players

Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction

Visit our report store at – https://www.growthplusreports.com/report-store

Browse more latest healthcare reports:

Anticholesteremic Agents Market by Drug Class (Bile Acid Resins, Statins), Distribution Channel (Hospital Pharmacies, Retail Pharmacies) – Global Outlook & Forecast 2023-2031

Glucose Elevating Agents Market by Products (Glucagon, Diazoxide), Indication (Hypoglycemia, Insulinoma), Route of Administration (Oral, Parenteral), Distribution Channel (Hospital Pharmacies, Retail Pharmacies), – Global Outlook & Forecast 2023-2031

Expat Health Insurance Market by Service Provider (Private, Public), Indication (Emergency Medical Evacuation, Maternity Coverage, Outpatient Coverage), Term Plan (Short-Term, Long-Term) – Global Outlook & Forecast 2023-2031

Veterinary Euthanasia Drugs Market by Animal Type (Companion Animals and Farm Animals), Route of Administration (Injectable Euthanasia Drugs, Inhalational Euthanasia Drugs) – Global Outlook & Forecast 2023-2031

MISME Syndrome Market by Treatment (Surgery, Radiotherapy, Pharmacotherapy) – Global Outlook & Forecast 2023-2031

About Us:

Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).

Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.

We were awarded by the prestigious CEO Magazine as “Most Innovative Healthcare Market Research Company in 2020”.